MLF 541

B. Braun Melsungen AG · Phase 3 active Small molecule

MLF 541 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or inflammatory pathway to modulate immune response.

At a glance

Generic name	MLF 541
Sponsor	B. Braun Melsungen AG
Modality	Small molecule
Therapeutic area	Immunology
Phase	Phase 3

Mechanism of action

While the exact molecular target of MLF 541 is not widely disclosed in public literature, it is being developed by B. Braun Melsungen AG as an immunomodulatory therapeutic in phase 3 clinical trials. The drug likely works by binding to a cell surface antigen or receptor involved in immune regulation, thereby enhancing or suppressing immune cell activity depending on the target and therapeutic context.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of a PN Regimen Containing n-3 Fatty Acid in Patients Considered After GI Surgery (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MLF 541 CI brief — competitive landscape report
MLF 541 updates RSS · CI watch RSS
B. Braun Melsungen AG portfolio CI